51 results about "CCR8" patented technology

Provided herein are various embodiments relating to anti-CCR8 binding agents, that bind to CCR8, and uses thereof. Some of the embodiments include antibodies, fragments thereof, variants thereof, derivatives thereof, and binding polypeptides targeting the same that bind CCR8. Such anti-CCR8 binding agents can be used in methods to treat, for example, cancer.

The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof, which specifically binds to human CCR8 and is an antagonist, particularly an insurmountable antagonist, of the CCL1-CCR8 signaling pathway. The invention also relates to the antibody or antigen-binding fragment for use in therapy, particularly in the treatment of cancer.

An anti-CCR8 antibody or antigen-binding fragment thereof. The anti-CCR8 antibody can recognize human CCR8 protein, block the signal pathway between CCR8 and CCL1 / CCL18, and recognize cells expressing CCR8, and also has target specific ADCC activity on target cells expressing CCR8.

This disclosure relates to a stable pharmaceutical formulation of an anti-human CCR8 monoclonal antibody and its use. The pharmaceutical formulation of the anti-human CCR8 antibody described herein is highly stable and can meet pharmaceutical use requirements even after long-term storage, high or low temperatures, freeze-thaw cycles, and shaking, and is expected to have a wide range of applications.

The present application relates to the technical field of biology, and discloses an anti-CCR8 antibody or an antigen binding fragment thereof, and a use thereof. The antibody can specifically bind to at least one epitope of CCR8, can also bind to Treg cells, has ADCC activity, and provides new possibilities for the treatment and / or prevention of cancer.

Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.

This disclosure provides antibodies that specifically bind to CCR8, antibody fragments, their antigen-binding portions, and their related applications. The anti-CCR8 antibody disclosed herein possesses the differentiated advantage of targeting CCR8 and has promising application prospects, enabling the provision of more drug options and treatment regimens for cancer patients.

The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.

The present invention provides anti-CC motif chemokine receptor 8 (CCR8) antigen-binding molecules (e.g., bispecific antigen-binding molecules) and compositions thereof. The present invention also features polynucleotides, vectors, host cells, production methods, pharmaceutical compositions, methods for treating diseases or disorders such as cancer, methods for depleting regulatory T cells, compositions for related applications and uses, and kits for use in conjunction with one or more methods.

The invention belongs to the field of biological medicine. Specifically, the invention provides an antibody targeting CCR8 and application of the antibody. More specifically, the invention provides an antibody targeting CCR8, STAR and CAR derived from the antibody, a therapeutic immune cell comprising the STAR or CAR, and applications thereof in disease treatment.

The invention discloses an anti-CCR8 antibody or an antigen binding fragment thereof and application thereof, and relates to the technical field of biology. The antibody can specifically bind to at least one epitope of CCR8, can also bind to Treg cells, has ADCC activity, and provides new possibility for treatment and / or prevention of cancers.

The present invention relates to medical uses comprising the administration of anti-human CCR8 antibodies in specifically defined dosage regimens in monotherapy or combination therapy with an anti-PD-(L)1 antibody. The dosing schemes were developed for anti-human / cynomolgus CCR8 antibody TPP-23411, but they can also be used for other antibodies having similar properties as TPP-23411. The medical uses or dosage regimens may comprise a stratification step to select patients with an increased probability of treatment success. Suggested biomarkers are a) Tumor Proportion Score or Combined Positive Score as a measure for PD-(L)1 expression, b) analysing in a blood, plasma or serum sample inflammatory cytokines and c) previous treatment of the cancer for at least 6 months with an anti-PD-(L)1 antibody. Furthermore, provided are anti-human CCR8 antibody-based medical uses and treatment methods comprising the administration of a Zr-89-labeled anti-CD8 minibody to determine the abundance and / or distribution of CD8 cells by means of a PET scan for stratification or for monitoring treatment success or disease progression. Also provided is a method to reliably determine an anti-anti-CCR8 antibody in cynomolgus or human plasma. Finally, an anti-murine CCR8 surrogate antibody is disclosed that mimics the unusual half-life of TPP-23411.

Provided is an antibody-drug conjugate represented by formula (1), or a pharmaceutically acceptable salt thereof. [wherein mAb represents an antibody that binds to CCR8, or a fragment thereof; n represents an integer from 1 to 8; L represents a group represented by formula (L-1), (L-2), (L-3) or (L-4); and Z represents a group represented by formula (Z-1), (Z-2) or (Z-3).]

The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.

To provide antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same.SOLUTION: Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof. Certain aspects of the present disclosure are directed to antibodies or antigen-binding portions thereof that specifically bind one or more amino acids within the N-terminal extracellular domain of human CCR8.SELECTED DRAWING: None

To provide antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same.SOLUTION: Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof. Certain aspects of the present disclosure are directed to antibodies or antigen-binding portions thereof that specifically bind one or more amino acids within the N-terminal extracellular domain of human CCR8.SELECTED DRAWING: None

Provided herein are various embodiments relating to antibodies and fusion proteins and their uses. Some embodiments include antibodies that bind to CCR8. Some embodiments include fusion proteins that bind to CCR8. Such antibodies and fusion proteins can be used in methods of treating, for example, cancer.

The present application relates to an antibody or an antigen-binding fragment thereof capable of specifically binding to CCR8 or TIGIT, and an immunoconjugate, a pharmaceutical composition and a multispecific antibody comprising the same. Further, the present application also relates to a multispecific antibody capable of specifically binding to CCR8 and TIGIT, and uses thereof.

The present invention relates to monoclonal antibodies or antigen-binding fragments thereof that specifically bind to human CCR8, and are antagonists of the CCL1-CCR8 signaling pathway, in particular wherein the antibody or antigen-binding fragment specifically binds to human CCR8, irrespective of the presence or absence of a post-translational modification, such as a sulfated tyrosine residue at position 15, 16 and / or 17 of the human CCR8. The invention also relates to antibodies or antigen-binding fragments for use in therapy, in particular in the treatment of cancer.

This application provides isolated antibodies (Abs), e.g., monoclonal antibodies (mAbs), that bind specifically to C—C Motif Chemokine Receptor 8 (CCR8), and bispecific antibodies targeting CCR8 and CTLA-4, and methods for treating a cancer in a subject comprising administering to the subject an anti-CCR8 Ab as monotherapy or in combination with an anticancer agent such as an immune checkpoint inhibitor.

The present invention provides anti-C-C motif chemokine receptor 8 (CCR8) antigen binding molecules (e.g., bispecific antigen binding molecules) and compositions thereof. The invention also relates to polynucleotides, vectors, host cells, methods of production, pharmaceutical compositions, methods of treating a disease or condition, such as cancer, methods of depleting regulatory T cells, related uses and compositions for use, and kits for use in one or more methods.

The present disclosure provides, inter alia, methods of treating a locally advanced, recurrent, or metastatic solid tumor malignancy in a subject in need thereof by administering an anti-CCR8 antibody to the subject, and related therapeutic uses.

The invention relates to antigen binding proteins and related fragments thereof for binding to CCR8, to production of said antigen binding proteins and fragments and to use of said antigen binding proteins and fragments for detection and therapy of various conditions.

The invention provides an antibody specifically binding to human CCR8 or an antigen binding fragment thereof and application thereof. The antibody or the antigen binding fragment thereof provided by the invention can be bound to the surface of a cell expressing CCR8 to block the binding of CCL1-CCR8, and can kill Treg through ADCC, and meanwhile, the antibody or the antigen binding fragment thereof has antitumor activity in a mouse MC38 colon cancer model.

This invention relates to monoclonal antibodies or antigen-binding fragments thereof that specifically bind to human CCR8 and are antagonists of the CCL1-CCR8 signaling pathway, particularly wherein the antibody or antigen-binding fragment specifically binds to human CCR8 regardless of the presence or absence of post-translational modifications (such as sulfated tyrosine residues at positions 15, 16, and / or 17 of human CCR8). The invention also relates to antibodies or antigen-binding fragments for therapeutic purposes, particularly for the treatment of cancer.

The present disclosure is directed to methods for treating a tumor or a cancer using antibodies or antigen-binding portions thereof that specifically bind human CCR8 and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods for treating cancer usinganti-CCR8 antibodies in combination with an additional anticancer agent, including methods of measuring and increasing levels of cytokines and cell surface markers and avoiding treatment emergent adverse events.

The present application provides a CCR8 antagonistic polypeptide compound, a pharmaceutical composition thereof, a kit and their uses. The CCR8 antagonistic polypeptide compound can be used for preventing or treating cancer or tumor, inflammatory disease, viral infection, IgG4-related disease, skin immune disease or its related symptoms.

The present application relates to an anti-CCR8 monoclonal antibody and application thereof, in particular, the present application relates to an anti-CCR8 monoclonal antibody which can be combined with CCR8 derived from primates. Further relates to a pharmaceutical composition comprising the anti-CCR8 monoclonal antibody, and application of the anti-CCR8 monoclonal antibody and / or the pharmaceutical composition in preventing and / or treating tumors or cancers.